Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP: 4.Examining 3-Year Update Data from the CASPIAN Trial

EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

Now Viewing

EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP: 12.Examining Key Data from DAREON-8

EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

1. B. Ideate-Lung02: Phase 3 Clinical Trial of Ifinatamab Deruxtecan vs TPC in Relapsed ES-SCL [TPS8126]
   1. Please share your perceptions of the potential for durable response to ifinatamab, a B7-H3-directed ADC in patients with previously treated, relapsed SCLC.
   2. How encouraging is an ORR of 52.4%, a 5.9-month median DoR, and a 12.2-month
   3. OS after a median 2 prior lines of therapy as reported in the Phase I/II trial?
   4. Currently, can you assay B7-H3 to determine individual expression levels?
   5. How does a treatment schedule of 12 mg/kg IV Q3W compare with that of:
   6. amrubicin [(Calsed) aminoanthracycline]: 45mg/m2 IV Infusion QD x 3 days Q3W [Japan]
   7. topotecan [(Hycamtin) topoisomerase inhibitor]: 1.5 mg/m2 IV infusion QD, Days 1-5 Q3W
   8. lurbinectedin [(Zepzelca) alkylating agent]: 3.2 mg/m2IV infusion Q3W
2. What is the potential for immunogenicity with this ADC, and which treatment-related adverse events would most concern you?